BioSpace News Archive

electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the company has submitted an Emergency Use Authorization (EUA) application to the U.S. Food and Drug Administration (FDA) to facilitate the study and clinical use of its gammaCore SapphireTM non-invasive vagus nerve stimulation therapy, or nVNS, for respiratory symptoms associated with COVID-19.

Emergent BioSolutions Inc. (NYSE:EBS) announced today that it has entered into a formal partnership with the U.S. government to expedite development of a plasma-derived therapy for patients with coronavirus disease 2019 (COVID-19).

Dilon Technologies® Inc., a world class global leader in breast cancer treatment and diagnosis and owner of the Navigator Gamma Probes has acquired substantially all the assets of Dune Medical, including Dune Medical’s “MarginProbe”.

Management to Host Conference Call / Webcast with Bronchiectasis Expert Dr. James Chalmers.

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) announces the completion of its acquisition of the core assets of Icagen’s North Carolina operations

Align Technology, Inc. (Nasdaq: ALGN) announced today that the Company will report first quarter 2020 financial results on Wednesday, April 29, 2020, after the close of market.

Kodiak Sciences Inc. (Nasdaq: KOD), a clinical stage biopharmaceutical company developing novel therapeutics to treat chronic, high-prevalence retinal diseases, today announced the appointment of Charles Bancroft to its board of directors.

Centene Corporation issued a reminder that it will release its 2020 first quarter financial results at approximately 6 a.m. on Tuesday, April 28, 2020, and host a conference call afterwards at approximately 8:30 a.m. to review the results.

Simulations Plus, Inc. (Nasdaq: SLP) announced today that it expects to file its quarterly report on Form 10-Q for the second quarter of its 2020 fiscal year, the period ended February 29, 2020, on Thursday, April 9, 2020.

Avivagen Inc. (TSXV:VIV) (“Avivagen” or the “Corporation”) announces that a total of 3,752 common shares will be issued at the rate of $0.61 per share to satisfy the maintenance fee of $2,280 owing in respect of the debentures issued on April 9, 2019.